Post-approval studies (Phase 4)UnknownNCT03274284What this trial is testingChemoradiotherapy for Recurrent T1G3 Bladder CancerWho this might be right forBladder Cancer Assiut University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06255964What this trial is testingIAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder CancerWho this might be right forBladder Cancer SUNHO（China）BioPharmaceutical CO., Ltd. 236
Testing effectiveness (Phase 2)Active Not RecruitingNCT03317158What this trial is testingModern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderWho this might be right forUrothelial CarcinomaBladder Cancer Noah Hahn, M.D. 186
Early research (Phase 1)WithdrawnNCT04109092What this trial is testingStimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102Who this might be right forUrinary Bladder Neoplasms Eisai Inc.
Testing effectiveness (Phase 2)Ended earlyNCT03519256What this trial is testingNivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderWho this might be right forUrinary Bladder Neoplasms Bristol-Myers Squibb 142
Testing effectiveness (Phase 2)Ended earlyNCT01625260What this trial is testingALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerWho this might be right forNon-muscle Invasive Bladder Cancer Altor BioScience 12
Testing effectiveness (Phase 2)Study completedNCT00003129What this trial is testingChemotherapy in Treating Patients With Early-Stage Bladder CancerWho this might be right forBladder Cancer Eastern Cooperative Oncology Group 75
Testing effectiveness (Phase 2)Study completedNCT04172675What this trial is testingErdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)Who this might be right forUrinary Bladder Neoplasms Janssen Research & Development, LLC 107
Large-scale testing (Phase 3)Ended earlyNCT02982395What this trial is testingStudy to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBCWho this might be right forNon Muscle Invasive Bladder Cancer Samyang Biopharmaceuticals Corporation 36
Not applicableEnded earlyNCT06026332What this trial is testingADSTILADRIN Early Utilization and Outcomes in the Real World SettingWho this might be right forBladder Cancer Ferring Pharmaceuticals 202
Early research (Phase 1)Study completedNCT01162785What this trial is testing1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder CancerWho this might be right forBladder Cancer M.D. Anderson Cancer Center 7
Early research (Phase 1)Study completedNCT03053635What this trial is testingIntravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) PatientsWho this might be right forNon-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG Theralase® Technologies Inc. 6
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591What this trial is testingStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinWho this might be right forNon Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer CG Oncology, Inc. 190
Large-scale testing (Phase 3)Study completedNCT01316874What this trial is testingIntravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)Who this might be right forCarcinoma in SituBladder Cancer Endo USA Inc., a Keenova Therapeutics Company 90
Large-scale testing (Phase 3)Looking for participantsNCT06545955What this trial is testingA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerWho this might be right forNon-muscle Invasive Bladder Cancer With Carcinoma in Situ Ferring Pharmaceuticals 250
Large-scale testing (Phase 3)Study completedNCT00406068What this trial is testingMycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder CancerWho this might be right forBladder Neoplasms Bioniche Life Sciences Inc. 129
Testing effectiveness (Phase 2)Active Not RecruitingNCT02202772What this trial is testingIntravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the BladderWho this might be right forUrothelial Carcinoma of the Urinary Bladder Guarionex J. Decastro 51
Large-scale testing (Phase 3)WithdrawnNCT02471495What this trial is testingRITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)Who this might be right forBladder Cancer Medical Enterprises Europe B.V.
Early research (Phase 1)Study completedNCT04798703What this trial is testingStudy of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)Who this might be right forBladder Carcinoma in Situ (CIS) Fidia Farmaceutici s.p.a. 20
Testing effectiveness (Phase 2)UnknownNCT03950362What this trial is testingBladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder CancerWho this might be right forNon-muscle-invasive Bladder Cancer Institut Paoli-Calmettes 67